Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study

Kensei Yamaguchi, Akira Sawaki, Toshihiko Doi, Taroh Satoh, Yasuhide Yamada, Yasushi Omuro, Tomohiro Nishina, Narikazu Boku, Keisho Chin, Yasuo Hamamoto, Hiroya Takiuchi, Yoshito Komatsu, Shigehira Saji, Wasaburo Koizumi, Yoshinori Miyata, Atsushi Sato, Eishi Baba, Takao Tamura, Takashi Abe, Atsushi Ohtsu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data. Methods: Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately. Results: Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 % in the AVAGAST and 58.5 % in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea. Conclusions: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.

Original languageEnglish
Pages (from-to)175-182
Number of pages8
JournalGastric Cancer
Volume16
Issue number2
DOIs
Publication statusPublished - 2013 Apr

Keywords

  • Capecitabine
  • Cisplatin
  • Gastric cancer
  • Japanese patients
  • Subset analysis

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, K., Sawaki, A., Doi, T., Satoh, T., Yamada, Y., Omuro, Y., Nishina, T., Boku, N., Chin, K., Hamamoto, Y., Takiuchi, H., Komatsu, Y., Saji, S., Koizumi, W., Miyata, Y., Sato, A., Baba, E., Tamura, T., Abe, T., & Ohtsu, A. (2013). Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer, 16(2), 175-182. https://doi.org/10.1007/s10120-012-0167-0